Clinical Trial Update: Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of genomic-guided therapy with dasatinib or nilutamide in metastatic castration-resistant prostate cancer has been terminated. Results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Nilandron (nilutamide)
• Sprycel (dasatinib)

Snippet

Sponsor: Duke University | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-10-29